Federal Register / Vol. 83, No. 246 / Wednesday, December 26, 2018 / Notices 66267 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Sherri Berger, 

Chief Operating Officer, Centers for Disease 

Control and Prevention. 

[FR Doc. 2018–27895 Filed 12–21–18; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended, and the Determination of 

the Chief Operating Officer, CDC, 

pursuant to Public Law 92–463. The 

grant applications and the discussions 

could disclose confidential trade secrets 

or commercial property such as 

patentable material, and personal 

information concerning individuals 

associated with the grant applications, 

the disclosure of which would 

constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Disease, 

Disability, and Injury Prevention and 

Control Special Emphasis Panel (SEP)- 

PS19–003, Using Real-time Prescription 

and Insurance Claims Data to Support 

the HIV Care Continuum. 

Dates: March 6–7, 2019. 

Time: 10:00 a.m.–5:00 p.m., (EDT). 

Place: Teleconference, Centers for Disease 

Control and Prevention, Room 1080, 8 

Corporate Square Blvd., Atlanta, GA 30329. 

Agenda: To review and evaluate grant 

applications. 

For Further Information Contact: Gregory 

Anderson, M.S., M.P.H., Scientific Review 

Officer, CDC, 1600 Clifton Road NE, Mailstop 

E60, Atlanta, Georgia 30333, (404) 718–8833, 

gca5@cdc.gov. 

The Chief Operating Officer, Centers for 

Disease Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for both 

the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Sherri Berger, 

Chief Operating Officer, Centers for Disease 

Control and Prevention. 

[FR Doc. 2018–27896 Filed 12–21–18; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[30Day–19–18ANU] 

Agency Forms Undergoing Paperwork 

Reduction Act Review 

In accordance with the Paperwork 

Reduction Act of 1995, the Centers for 

Disease Control and Prevention (CDC) 

has submitted the information 

collection request titled Communities 

Organized To Prevent Arboviruses: 

Assessment of Knowledge, Attitudes, 

and Vector Control Practices and SeroPrevalence and Incidence of Arboviral 

Infection in Ponce, Puerto Rico (COPA 

Study) to the Office of Management and 

Budget (OMB) for review and approval. 

CDC previously published a ‘‘Proposed 

Data Collection Submitted for Public 

Comment and Recommendations’’ 

notice on July 20, 2018 to obtain 

comments from the public and affected 

agencies. CDC did not receive comments 

related to the previous notice. This 

notice serves to allow an additional 30 

days for public and affected agency 

comments. 

CDC will accept all comments for this 

proposed information collection project. 

The Office of Management and Budget 

is particularly interested in comments 

that: 

(a) Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

(b) Evaluate the accuracy of the 

agencies estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

(c) Enhance the quality, utility, and 

clarity of the information to be 

collected; 

(d) Minimize the burden of the 

collection of information on those who 

are to respond, including, through the 

use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic submission of 

responses; and 

(e) Assess information collection 

costs. 

To request additional information on 

the proposed project or to obtain a copy 

of the information collection plan and 

instruments, call (404) 639–7570 or 

send an email to omb@cdc.gov. Direct 

written comments and/or suggestions 

regarding the items contained in this 

notice to the Attention: CDC Desk 

Officer, Office of Management and 

Budget, 725 17th Street NW, 

Washington, DC 20503 or by fax to (202) 

395–5806. Provide written comments 

within 30 days of notice publication. 

Proposed Project 

Communities Organized To Prevent 

Arboviruses: Assessment of Knowledge, 

Attitudes, and Vector Control Practices 

and Sero-Prevalence and Incidence of 

Arboviral Infection in Ponce, Puerto 

Rico (COPA)—Existing Collection in use 

without an OMB Control Number— 

National Center for Emerging and 

Zoonotic Infectious Diseases (NCEZID), 

Centers for Disease Control and 

Prevention (CDC). 

Background and Brief Description 

Recent years have seen the emergence 

of two epidemic arthropod-borne 

viruses (arboviruses) that are 

transmitted by Aedes aegypti 

mosquitoes. Chikungunya virus was 

introduced into the Caribbean in late 

2013, and caused large epidemics of 

fever with severe joint pain throughout 

the Caribbean and Americas in 2014. 

Zika virus was first detected in the 

Americas in Brazil in 2014, spread 

throughout the Americas, and has since 

been associated with devastating birth 

defects, Guillain-Barre syndrome, and is 

the first arbovirus that can also be 

transmitted through sexual contact. In 

addition, the four viruses that cause 

dengue were introduced to the Americas 

over the past several hundred years and 

have since become endemic, and yellow 

fever virus has recently caused large 

outbreaks in Brazil and there is risk of 

importation to other counties in the 

Americas. 

In all of these cases, the public health 

response to the spread of these 

arboviruses throughout the tropics, 

where their mosquito vectors thrive, has 

been hampered by a lack of sustainable 

and effective interventions to prevent 

infection with any of these arboviruses 

at the community level. Additionally, 

the rapid speed with which new 

arboviruses spread does not often 

provide the time needed to plan and 

implement community-level 

interventions to decrease disease 

transmission. Although several 

candidate vaccines for chikungunya and 

Zika are currently in clinical 

development, none are yet available. A 

dengue vaccine has been licensed in 

several countries, but initial analyses 

have suggested that decades will be 

needed before it results in reduction in 

transmission of dengue virus. 

In recent years, community based 

strategies for vector control have been 


amozie on DSK3GDR082PROD with NOTICES1